Company intelligence / Profile preview

ECI Biotech

Worcester, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

ECI Biotech has developed proprietary diagnostic sensors ("ExpressDetect") targeting microbial pathogens and a therapeutic platform leveraging platelet-rich plasma-derived growth factors combined with chitosan or hyaluronic acid excipients. Their pipeline includes preclinical/early clinical programs focused on ophthalmology and wound care. No published clinical trial results or commercial approvals are noted in public sources as of now.

Therapeutic areas: DermatologyOphthalmology
Modalities: Protein sensor technology (for diagnostics and therapeutics)Plasma-derived growth factor therapyChitosan-based delivery systemsHyaluronic acid-based delivery systemsRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on ECI Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECI Biotech.

Explore the full profile